Filamin-a is required to mediate SST2 effects in pancreatic neuroendocrine tumours

Research output: Contribution to journalArticlepeer-review

Abstract

Somatostatin receptor type 2 (SST2) is the main pharmacological target of somatostatin (SS) analogues widely used in patients with pancreatic neuroendocrine tumours (P-NETs), this treatment being ineffective in a subset of patients. Since it has been demonstrated that Filamin A (FLNA) is involved in mediating GPCR expression, membrane anchoring and signalling, we investigated the role of this cytoskeleton protein in SST2 expression and signalling, angiogenesis, cell adhesion and cell migration in human P-NETs and in QGP1 cell line. We demonstrated that FLNA silencing was not able to affect SST2 expression in P-NET cells in basal conditions. Conversely, a significant reduction in SST2 expression (-43±21%, P

Original languageEnglish
Pages (from-to)181-190
Number of pages10
JournalEndocrine-Related Cancer
Volume23
Issue number3
DOIs
Publication statusPublished - Mar 1 2016

Keywords

  • Filamin A
  • Neuroendocrine tumours
  • Somatostatin
  • Somatostatin receptor type 2

ASJC Scopus subject areas

  • Endocrinology
  • Oncology
  • Cancer Research
  • Endocrinology, Diabetes and Metabolism

Fingerprint Dive into the research topics of 'Filamin-a is required to mediate SST2 effects in pancreatic neuroendocrine tumours'. Together they form a unique fingerprint.

Cite this